Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Open - Angle Glaucoma (POAG) Clear all

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Open Angle Glaucoma
Interventions: Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane; Drug
Lead sponsor: Center for Sight Las Vegas; Other
Eligibility: 40 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 13
States / cities: Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more

Conditions: Glaucoma, Primary Open Angle, Cataract
Interventions: Intracanalicular Dexamethasone, 0.4 mg insert; Drug
Lead sponsor: Wolstan and Goldberg Eye Associates; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Torrance, California

Conditions: Pigmentary Glaucoma, Primary Open Angle Glaucoma, Cataract
Interventions: Trabeculectomy, Trabeculectomy and cataract surgery, Cataract surgery; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: OTX-TIC; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Petaluma, California • Torrance, California • Roswell, Georgia + 2 more

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension
Interventions: Selective Laser Trabeculoplasty; Device
Lead sponsor: Northeastern State University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tahlequah, Oklahoma

Conditions: Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions: anterior segment OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Hypertension, Glaucoma, Open-Angle
Interventions: Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Morrow, Georgia • High Point, North Carolina • Mt. Pleasant, South Carolina

Conditions: Primary Open Angle Glaucoma
Interventions: XEN63 Glaucoma Treatment System; Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Culver City, California • Petaluma, California + 25 more

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: T-2345, Xalatan; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: Caffeinated Coffee, Decaffeinated Coffee; Other
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 89 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Ocular Hypertension
Interventions: INO-8875, Placebo; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: AqueSys XEN 45 Glaucoma Implant; Device
Lead sponsor: AqueSys, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more

Conditions: Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions: Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant; Drug · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open-Angle
Interventions: Methazolamide 25 MG, Methazolamide 50 MG; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Open-Angle Glaucoma
Interventions: Stents, Laser, Laser Trabeculoplasty; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 35 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more

Conditions: Primary Open-angle Glaucoma
Interventions: iStent supra, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 45 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Racine, Wisconsin

Search by objective public record fields.

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

Autoimmune Dysregulation in Pigmentary Glaucoma

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

Topical Insulin for Glaucoma (TING2)

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

Imaging Lens Deposits in Exfoliation Syndrome

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Excimer Laser Trabeculostomy Glaucoma Treatment Study

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

The Effects of Caffeinated Coffee on Intraocular Pressure

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

Ahmed Glaucoma Valve Surgery With Mitomycin-C

Use of Methazolamide to Lower Intraocular Pressure

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery